PGEN: Precigen, Inc. Growth-Adjusted Market Cap to Net Income
Geopolitical tensions are undermining international clinical trial networks, restricting access to cancer therapies. The P/E to growth ratio chart visualizes this trend, where 0.00 captures the magnitude of this parameter. Precigen, Inc. (PGEN) ensures production stability through its own US-based bio-manufacturing facility, yet the absence of commercial products leaves the company dependent on external financing and grants.
Metric breakdowns and analytics for Precigen, Inc. (PGEN)
- share price and consensus valuation forecast:
- market capitalization information:
- company book value details:
- issuer credit burden and liquidity indicators:
- business earnings and investment ratios data:
PGEN - Net Profit|Expected Net Profit Precigen, Inc.|PGEN - P/E Multiple|Projected Price to Earnings Precigen Corp|PGEN - PEG Multiple|Total Company Value to Operating Income Before Depreciation Ratio Intrexon|PGEN - Operating profit EBITDA|Net earnings per share for the trailing year Precigen|PGEN - Net earnings per share (EPS TTM)|Earnings per share growth in annualized terms for the last twelve months precigen.com|PGEN - Earnings per share growth in current year|Projected earnings per share growth rate for next year Precigen, Inc.
General company analysis:PGEN - Precigen Inc
This indicator compares the current market P/E multiple with expected earnings growth, identifying undervalued assets when values fall below one. By analyzing the PEG ratio, an investor can assess the growth potential of Precigen, Inc. (PGEN), where the high technological value of the proprietary UltraCAR-T platform must be balanced against the risks of passing rigorous FDA clinical trials.
Competitors of Precigen, Inc.
ARGX (argenx N.V.) - Growth-Adjusted Payback Ratio|PEG Multiple BNTX (BioNTech Group)|Growth-Adjusted Market Cap to Net Income Abivax (ABVX)|ADMA - Price/Earnings to Growth Ratio|protagonist-inc.com (PTGX) - Price/Earnings to Growth Multiple|Immunovant (IMVT) - Price/Earnings to Growth Ratio|Price/Earnings to Growth Multiple Kiniksa Pharmaceuticals, Ltd.|Price/Earnings to Growth Multiple GRFS|PEG Multiple Adaptive Biotechnologies Inc.|Price/Earnings to Growth Ratio Celldex Therapeutics (CLDX)|auriniapharma.com - Growth-Adjusted P/E Ratio|PEG Multiple BCRX (BioCryst Pharmaceuticals)|Vera Therapeutics Inc (VERA) - Price to Earnings Adjusted for Growth Rate|DNTH - Price/Earnings to Growth Ratio|Market Cap to Earnings and Growth Ratio PHVS|abcellera.com (ABCL) - Price/Earnings to Growth Ratio|tourmalinebio.com - Growth-Adjusted Payback Ratio|PHAR (Pharming Group) - PEG Multiple|Price to Earnings Adjusted for Growth Rate Nektar Therapeutics Inc NKTR|PEG Multiple UPB|Price/Earnings to Growth Multiple Zenas Corp ZBIO|PEG Multiple IMNM (Immunome, Inc.)|Growth-Adjusted Market Cap to Net Income gossamerbio.com (GOSS)|KalVista Pharmaceuticals, Inc. - PEG Multiple|Price to Net Income Growth Ratio Septerna, Inc. (SEPN)|PVLA: PEG Multiple|Price to Earnings Adjusted for Growth Rate Savara Pharma (SVRA)|Price/Earnings to Growth Ratio Rigel Pharmaceuticals|Growth-Adjusted P/E Ratio ANAB (anaptysbio.com)|Price/Earnings to Growth Multiple ATXS (Astria Therapeutics, Inc.)|ENGN (enGene Holdings Inc) - Growth-Adjusted Payback Ratio|PEG Multiple RAPT (RAPT Therapeutics, Inc.)|Growth-Adjusted Market Cap to Net Income Aerovate Therapeutics, Inc. (JBIO)|ACRS - Price/Earnings to Growth Ratio|KYTX (kyvernatx.com) - Growth-Adjusted P/E Ratio|TLSA: PEG Multiple|Price/Earnings to Growth Multiple Cabaletta Bio Inc.|Price/Earnings to Growth Multiple VTYX|Theratechnologies, Inc (THTX) - Growth-Adjusted Market Cap to Net Income|Price/Earnings to Growth Ratio Avalo Therapeutics, Inc (AVTX)|ELDN: Market Cap to Earnings and Growth Ratio|PEG Multiple AGEN (Agenus Inc.)|Price to Net Income Growth Ratio Climb Bio Inc.|Zura Bio Limited - PEG Multiple|Price to Earnings Adjusted for Growth Rate aTyr Pharmaceuticals|adagene.com (ADAG) - Price/Earnings to Growth Ratio|Growth-Adjusted P/E Ratio IMA|Price/Earnings to Growth Ratio Shattuck Labs Inc|Equillium Bio - Market Cap to Earnings and Growth Ratio|PEG Multiple CNTB|IMUX (immunic-therapeutics.com) - Growth-Adjusted Payback Ratio|PEG Multiple ATRA (Atara Bio)|PEG Multiple InflaRx NV IFRX|XFOR - Price/Earnings to Growth Ratio|Growth-Adjusted Payback Ratio ACET (Adicet Bio)|celularity.com (CELU) - Price/Earnings to Growth Ratio|Price/Earnings to Growth Multiple INmune Bio Corporation|BRNS (Barinthus Biotherapeutics) - PEG Multiple|PEG Multiple kezarlifesciences.com|Price/Earnings to Growth Multiple SABS (SAB Biotherapeutics, Inc.)|AKTX (Akari Therapeutics PLC) - Growth-Adjusted Payback Ratio|PEG Multiple ENLV (Enlivex Therapeutics Ltd.)|Growth-Adjusted Market Cap to Net Income Q32 Bio Inc (QTTB)|GOVX - Price/Earnings to Growth Ratio|edesabiotech.com (EDSA) - Price/Earnings to Growth Multiple|iBio (IBIO) - Price/Earnings to Growth Ratio|Price/Earnings to Growth Multiple Carisma Therapeutics Inc.|Price/Earnings to Growth Multiple XTLB|PEG Multiple Bolt Bio|Price/Earnings to Growth Ratio HCW Biologics Inc. (HCWB)|aptevotherapeutics.com - Growth-Adjusted P/E Ratio|PEG Multiple AIM (AIM ImmunoTech)|Aditxt Inc. (ADTX) - Price to Earnings Adjusted for Growth Rate|GRI - Price/Earnings to Growth Ratio|Market Cap to Earnings and Growth Ratio XRTX|Vyome Holdings Inc (HIND) - Price/Earnings to Growth Ratio|revbiosciences.com - Growth-Adjusted Payback Ratio|INDP (Indaptus Therapeutics, Inc.) - PEG Multiple|Price to Earnings Adjusted for Growth Rate Scinai Immunotherapeutics Ltd SCNI|PEG Multiple CALI|Price/Earnings to Growth Multiple affimed.com AFMD|PEG Multiple ALLK (Allakos)|Growth-Adjusted Market Cap to Net Income HOOKIPA Pharma, Inc. (HOOK)|IGM Bio - PEG Multiple|Price to Net Income Growth Ratio iTeos Therapeutics Inc (ITOS)|OCEA: PEG Multiple|Price to Earnings Adjusted for Growth Rate TC BioPharm Ltd (TCBP)|Price/Earnings to Growth Ratio Third Harmonic Bio
